Second Quarter Earnings Call Supplemental Information August 7, 2024 Disclaimer Forward looking statements Statements contained in this presentation which are not historical facts, such as those relating to future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All such estimates, projections, and forward-looking information speak only ...

| --- | --- | --- | --- | |----------------------------------------|-------|-------|---------------------------------------| | | | | | | | | | | | Second Quarter 2024 Financial Results | | | MKS Instruments, Inc. August 8, 2024 | | | | | | Safe Harbor for Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 ...

| --- | --- | |-----------------------|-------| | | | | ChromaDex | | | | | | | | | Earnings Presentation | | | Second Quarter 2024 | | Rob Fried Chief Executive Officer James Lee Interim Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | August 7, 2024 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securities ...

AERSALE CORPORATION Investor Presentation Important notices and disclaimers Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. AerSale's actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budge ...

Amdocs Limited NASDAQ: DOX Fiscal Q3 2024 Earnings Presentation August 7, 2024 Shuky Sheffer President & CEO Tamar Rapaport-Dagim CFO & COO The information contained herein in this presentation or delivered or to be delivered to you during this presentation does not constitute an offer, expressed or implied, or a recommendation to do any transaction in Amdocs Limited securities or in any securities of its affiliates or subsidiaries. 2 Information Security Level 0 – Public. © 2024 – Proprietary & Confidentia ...

| --- | --- | |-----------------------------------------------|-------| | | | | | | | | | | | | | | | | Q2 2024 Earnings Conference Call NASDAQ EQIX | | | Presented on August 7, 2024 | | | © 2024 Equinix, Inc. | | Public Disclosure Statement Forward-Looking Statements Except for historical information, this presentation contains forward-looking statements which include words such as "believe," "anticipate," and "expect". These forward-looking statements involve risks and uncertainties that may cause Equinix ...

Second Quarter 2024 Results © 2024 Aeva, Inc. Legal Disclaimer Forward-looking Statements This presentation contains certain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking ...

DocGo Announces Record Second Quarter 2023 Results August 7, 2023 at 4:05 PM EDT Company Raises 2023 Revenue Guidance To $540-$550 Million Increases Adjusted EBITDA1 Guidance To $48-$53 Million NEW YORK--(BUSINESS WIRE)--Aug. 7, 2023-- DocGo Inc. (Nasdaq: DCGO), a leading provider of last-mile mobile health services today announced financial and operating results for the quarter ended June 30, 2023. Q2 2023 Financial Highlights Total revenue for the second quarter of 2023 was $125.5 million, up from $113.0 ...

| --- | --- | --- | --- | |-----------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | PacBio Q2 2024 Earnings | | | | | | | | | | Presentation August 7, 2024 Second Quarter 2024 Earnings Call | | | | | | | | | | | | | | | | | | | | | | | | 1 Statement regarding use of non‐GAAP financial measures PacBio reports non‐GAAP results for basic and diluted net income and loss per share, net income, net loss, gross margins, ...

DIGITALBRIDGE 1 EARNINGS PRESENTATION 2Q 2024 August 7, 2024 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation may contain forward-looking statements within the meaning of the federal securities laws, including statements relating to (i) our strategy, outlook and growth prospects, (ii) our operational and financial targets and (iii) general economic trends and trends in our industry and markets. Forward-looking statements relate to expectations, beliefs, projections, future plans a ...